Literature DB >> 10022247

Polymorphism of phase II enzymes: identification of new enzymes and polymorphic variants by database analysis.

P Board1, A Blackburn, L S Jermiin, G Chelvanayagam.   

Abstract

The Phase II enzymes of xenobiotic metabolism are characterized by a high level of substrate diversity and genetic polymorphism. Genetic polymorphism of the Phase II enzymes can be of substantial clinical significance as some variants have differences in substrate specificity, stability and levels of expression. Variation in these factors can give rise to abnormal drug metabolism and susceptibility to carcinogens and toxins. A new approach to the discovery of additional members of Phase II enzyme families and the identification of polymorphic variants using searches of the EST databases has been investigated. The examples provided demonstrate that relatively simple search strategies can be highly productive.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10022247     DOI: 10.1016/s0378-4274(98)00300-2

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  3 in total

1.  Model Informed Dose Optimization of Dichloroacetate for the Treatment of Congenital Lactic Acidosis in Children.

Authors:  Naveen Mangal; Margaret O James; Peter W Stacpoole; Stephan Schmidt
Journal:  J Clin Pharmacol       Date:  2017-09-15       Impact factor: 3.126

Review 2.  Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily.

Authors:  D Sheehan; G Meade; V M Foley; C A Dowd
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

3.  Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross-Sectional Descriptive Study as Part of the PharmLines Initiative.

Authors:  Muh Akbar Bahar; Jens H J Bos; Sander D Borgsteede; Aafje Dotinga; Rolinde A Alingh; Bob Wilffert; Eelko Hak
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.